Israel - hebraico - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) orb: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicate

Israel - hebraico - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Israel - hebraico - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 200 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti)- containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Israel - hebraico - Ministry of Health

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

Israel - hebraico - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

Israel - hebraico - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).

Israel - hebraico - Ministry of Health

gsk consumer healthcare, israel ltd - ibuprofen - קפסולות ממולאות נוזל - ibuprofen 200 mg - ibuprofen - ibuprofen - for the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. antipyretic. antiinflammatory for rheumatic diseases.

Israel - hebraico - Ministry of Health

gsk consumer healthcare, israel ltd - calcium carbonate - טבליות לעיסות - calcium carbonate 1000 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

Israel - hebraico - Ministry of Health

gsk consumer healthcare, israel ltd - calcium carbonate - טבליות לעיסות - calcium carbonate 750 mg - calcium carbonate - calcium carbonate - treatment of heartburn, calcium supplement.

Israel - hebraico - Ministry of Health

baxter healthcare distribution ltd., israel - arginine; calcium chloride dihydrate; glycine; histidine; isoleucine; l- alanine; leucine; lysine hydrochloride; magnesium chloride hexahydrate; methionine; phenylalanine; proline; serine; sodium (s) - lactate; sodium chloride; threonine; tryptophan; tyrosine; valine - תמיסה לדיאליזה פריטוניאלית - tyrosine 0.3 g/l; tryptophan 0.27 g/l; phenylalanine 0.57 g/l; threonine 0.646 g/l; serine 0.51 g/l; proline 0595 g/l; glycine 0.51 g/l; l- alanine 0.951 g/l; valine 1.393 g/l; methionine 0.85 g/l; isoleucine 0.85 g/l; leucine 1.02 g/l; histidine 0.714 g/l; arginine 1.071 g/l; sodium chloride 5.38 g/l; lysine hydrochloride 0.955 g/l; calcium chloride dihydrate 0.184 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium (s) - lactate 4.480 g/l - combinations of electrolytes - combinations of electrolytes - nutritional supplement for malnourished renal failure patients (albumin concentration lower then 35 g/liter) being maintained on peritoneal dialysis.